TICAGRELOR

/static/temp/default.svg

Search structure


Trade Names	BRILINTA TICAGRELOR
Synonyms	AR-C126532XX AZD-6140 AZD6140 Brilinta Brilique Possia Ticagrelor
Status
Molecule Category	UNKNOWN
ATC	B01AC24
UNII	GLH0314RVC


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	OEKWJQXRCDYSHL-FNOIDJSQSA-N
Smiles	CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1
InChI	InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C23H28F2N6O4S
Molecular Weight	522.58
AlogP	2.01
Hydrogen Bond Acceptor	11.0
Hydrogen Bond Donor	4.0
Number of Rotational Bond	10.0
Polar Surface Area	138.44
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	36.0

Bioactivity

Mechanism of Action	Action	Reference
Purinergic receptor P2Y12 negative allosteric modulator	NEGATIVE ALLOSTERIC MODULATOR	FDA


Protein: Purinergic receptor P2Y12 Description: P2Y purinoceptor 12 Organism : Homo sapiens Q9H244 ENSG00000169313

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Nucleotide-like receptor (family A GPCR) Purine receptor	-	5-5140	-	2-14	-

Assay Description	Organism	Bioactivity	Reference
Displacement of [125I] labeled ligand from human P2Y12 receptor in human platelets	Homo sapiens	1.995 nM
Antiplatelet activity in Sprague-Dawley rat assessed as ex-vivo inhibition of ADP-induced platelet aggregation at 5 mg/kg, po at 0.5 hrs by Born's method relative to vehicle-treated control	Rattus norvegicus	66.27 %
Displacement of [33P]2-MeS-ADP from human recombinant P2Y12 receptor expressed in CHO cell membranes by scintillation counting method	Homo sapiens	14.0 nM
Inhibition of ADP-induced platelet aggregation in Sprague-Dawley rat plasma at 2.5 mg/kg, po treated 2.5 hrs prior to ADP-challenge measured after 2 mins by light transmission-based assay	Rattus norvegicus	59.0 %
Antagonist activity at P2Y12 receptor in human platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins prior to ADP-challenge by light transmission-based assay	Homo sapiens	500.0 nM
Antagonist activity at P2Y12 receptor (unknown origin)	Homo sapiens	5.012 nM
Inhibition of P2Y12 in human platelet rich plasma assessed as reduction in ADP-induced platelet aggregation pre-incubated before ADP addition and measured after 10 mins by Bruker spectrophotometry	Homo sapiens	320.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	34.26 %		SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	14.69 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.23 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.24 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.23 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.24 %
Inhibition of bovine xanthine oxidase assessed as reduction in uric acid formation at 10 uM using xanthine as substrate preincubated for 15 mins followed by substrate addition measured at 30 sec interval for upto 2 mins by spectrophotometric analysis relative to control	Bos taurus	50.0 %

Cross References

Resources	Reference
ChEBI	68558
ChEMBL	CHEMBL398435
DrugBank	DB08816
DrugCentral	4184
FDA SRS	GLH0314RVC
Human Metabolome Database	HMDB0015702
Guide to Pharmacology	1765
KEGG	D09017
PDB	TIQ
PharmGKB	PA165374673
PubChem	9871419
SureChEMBL	SCHEMBL1979652
ZINC	ZINC000028957444

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).